peptide analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-23. Numbers and descriptions here follow the published literature rather than marketing material.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Gamma irradiation is widely used due to its high penetration depth and dose uniformity, allowing for large-scale applications with high throughput. Additionally, gamma irradiation is significantly less expensive than using an X-ray source. In most designs, the radioisotope, contained in stainless steel pencils, is stored in a water-filled storage pool which absorbs the radiation energy when not in use. For treatment, the source is lifted out of the storage tank, and product contained in totes is passed around the pencils to achieve required processing. Treatment costs vary as a function of dose and facility usage. A pallet or tote is typically exposed for several minutes to hours depending on dose. Low-dose applications such as disinfestation of fruit range between US$0.01/lb and US$0.08/lb while higher-dose applications can cost as much as US$0.20/lb.
CaO + H2O → Ca(OH)2 Ca(OH)2 + CO2 → CaCO3 + H2O Calcium carbonate can be crystallized from calcium chloride (CaCl2), by placing an aqueous solution of CaCl2 in a desiccator alongside ammonium carbonate [NH4]2CO3. In the desiccator, ammonium carbonate is exposed to air and decomposes into ammonia, carbon dioxide, and water. The carbon dioxide then diffuses into the aqueous solution of calcium chloride, reacts with the calcium ions and the water, and forms calcium carbonate.
==== C. Nasal blood supply – arteries and veins ==== Like the face, the human nose is well vascularized with arteries and veins, and thus supplied with abundant blood. The principal arterial blood-vessel supply to the nose is two-fold: (i) branches from the internal carotid artery, the branch of the anterior ethmoidal artery, the branch of the posterior ethmoidal artery, which derive from the ophthalmic artery; (ii) branches from the external carotid artery, the sphenopalatine artery, the greater palatine artery, the superior labial artery, and the angular artery. The external nose is supplied with blood by the facial artery, which becomes the angular artery that courses over the superomedial aspect of the nose. The sellar region (sella turcica, "Turkish chair") and the dorsal region of the nose are supplied with blood by branches of the internal maxillary artery (infraorbital artery) and the ophthalmic arteries that derive from the internal common carotid artery system. Internally, the lateral nasal wall is supplied with blood by the sphenopalatine artery (from behind and below) and by the anterior ethmoid artery and the posterior ethmoid artery (from above and behind). The nasal septum also is supplied with blood by the sphenopalatine artery, and by the anterior and posterior ethmoid arteries, with the additional circulatory contributions of the superior labial artery and of the greater palatine artery.
=== Activators === 1-Aminoanthracene and propofol - activate SIRT2 activity on some substrates but inhibit it on others Nicotinamide riboside - activates SIRT2, but non selective Metformin - activates SIRT2 but has several other mechanisms of action as well SRT1720 - primarily a SIRT1 activator, but also weakly activates SIRT2 Hexapeptide-12 (VGVAPG) - upregulates SIRT2 gene expression through an indirect pathway
Sources: en.wikipedia.org
1. Leading theorists wedded to the standard interpretations that allow them to dominate their field, tend first to deny that the anomaly exists; at most, it is a 'blip', an unimportant or transient factor. Initially, structural Realists sought to deny that unipolarity was enduring or important, and predicted its quick demise. Waltz, Mearsheimer, and Layne all predicted in the early 1990s that other powers would soon emerge to balance the US.2. As the salience of the anomaly becomes undeniable, theoreticians redefine or shift their theoretical expectations, so as to contend that the anomaly can indeed be explained by their original theory even if their earlier writings ruled it out. More recently, many structural Realists have acknowledged the existence of unipolarity, or at least have acknowledged the absence of traditional balancing against the US, but have altered standard definitions of balancing behavior in order to reconcile this with balance-of-power theory. Thus, Mearsheimer suggested that Iran and North Korea are balancing, even though the "balance" is not in sight.3. Finally, a band of younger scholars, less invested professionally in the old theory, develops a new interpretation that not only explains the anomaly but places it at its theoretical center. This new theoretical interpretation supersedes the old one and becomes the new 'paradigm' for successive inquiry. In this manner, Robert Pape, T. V.
=== Storage === Because mRNA is fragile, some vaccines must be kept at very low temperatures to avoid degrading and thus giving little effective immunity to the recipient. Pfizer–BioNTech's BNT162b2 mRNA vaccine has to be kept between −80 and −60 °C (−112 and −76 °F). Moderna says their mRNA-1273 vaccine can be stored between −25 and −15 °C (−13 and 5 °F), which is comparable to a home freezer, and that it remains stable between 2 and 8 °C (36 and 46 °F) for up to 30 days. In November 2020, it was reported, "While it's possible that differences in LNP formulations or mRNA secondary structures could account for the thermostability differences [between Moderna and BioNtech], many experts suspect both vaccine products will ultimately prove to have similar storage requirements and shelf lives under various temperature conditions." Several platforms are being studied that may allow storage at higher temperatures.
=== Total synthesis === To summarize the total synthesis of Guanacastepene A, two independent synthetic routes are particularly relevant here. The first involves an attempt by Danishefsky and his colleagues to close the seven-membered B ring via an intramolecular Horner–Wadsworth–Emmons cyclization; however, this approach unexpectedly favored a kinetically preferred 5-exo cyclization instead. Ultimately, the seven-membered ring was formed via reductive cyclization of a vinyl iodide-ketone precursor, yielding the fused 5,7-ring hydroazulenone core. The quaternary stereocenter at C8 was then stereoselectively introduced via sequential Eschenmoser methylenation and conjugate cuprate addition. It was found that the order of alkylation determines the resulting stereochemistry. An intramolecular Knoevenagel cyclization was ultimately required to complete the guanacastane skeleton. This was achieved only after epoxidation of the corresponding olefin. This was followed by a Rubottom oxidation to introduce the characteristic acetoxy group at C13. The second, alternative, formal synthesis was developed by Hanna and his colleagues. Instead of forming the six- and seven-membered rings sequentially, they built the six- and seven-membered rings simultaneously in a single tandem ring-closing metathesis (RCM) reaction. Using a triene precursor, both quaternary stereocenters at C8 and C11 were established prior to the metathesis step. This was treated with the second-generation Grubbs catalyst in refluxing dichloromethane to directly yield the tricyclic skeleton.
Even moderate sustained use of alcohol may increase anxiety and depression levels in some individuals. In most cases these drug induced psychiatric disorders fade away with prolonged abstinence. A protracted withdrawal syndrome can also occur with psychiatric and other symptoms persisting for months after cessation of use. Among the currently prevalent medications, benzodiazepines are the most notable drug for inducing prolonged withdrawal effects with symptoms sometimes persisting for years after cessation of use. Prospective epidemiological studies do not support the hypotheses that comorbidity of substance use disorders with other psychiatric illnesses is primarily a consequence of substance use or dependence or that increasing comorbidity is largely attributable to increasing use of substances. Yet emphasis is often on the effects of substances on the brain creating the impression that dual disorders are a natural consequence of these substances. However, addictive drugs or exposure to gambling will not lead to addictive behaviors or drug dependence in most individuals but only in vulnerable ones, although, according to some researchers, neuroadaptation or regulation of neuronal plasticity, and molecular changes, may alter gene expression in some cases and subsequently lead to substance use disorders. Research instruments are also often insufficiently sensitive to discriminate between independent, true dual pathology, and substance-induced symptoms.
== History == Paniz-Mondolfi was born in Caracas, Venezuela in 1976. His mother is a pediatrician and his father an architect. His grandfather, Edgardo Mondolfi Otero, a biologist and zoologist. Two of his uncles were physicians with special ambitions in the field of sciences and research. His childhood was shared between Caracas and Kenya. Paniz-Mondolfi has a master's degree in parasitology and tropical diseases; he did international fellowships in microbiology, molecular genetics, and skin disease. He also did a second medical residency in the United States in pathology. He isolated and described a new species of parasite that had infected a NY resident, and a new mycobacterium that sickened two people in Connecticut. He earned an MD and PhD and studied under Jacinto Convit the leprosy researcher. He was a pathologist at the IDB Biomedical Research Institute in Barquisimeto, Venezuela until 2019 when he fled to the United States. He is the founder of the Venezuelan Science Incubator, an independent health research organization. Paniz-Mondolfi is assistant professor of pathology, molecular and cell-based medicine at the Mount Sinai Icahn School of Medicine. He is also affiliated with the Yale Cancer Center. In 2020 he focused his research on the COVID-19 pandemic and the effects the virus had on minority children. His research findings have been published in several medical journals including: the European Society of Clinical Microbiology and Infectious Diseases, The American Association for the Advancement of Science, and The Lancet.
Sources: en.wikipedia.org
== Timeline of detections == NPI was first identified in the UK in August 2024 by WEDINOS as samples W054816 and W057074, then the full chemical characterisation and first literature reported sample was provided by CanTEST in Australia in September 2024,. NPI was later detected in the Netherlands in May 2025, and in Finland in early 2025.
== Receptor binding and effect == The binding of ligands (drug) to receptors is governed by the law of mass action which relates the large-scale status to the rate of numerous molecular processes. The rates of formation and un-formation can be used to determine the equilibrium concentration of bound receptors. The equilibrium dissociation constant is defined by:
Dominion Voting Systems sues Mike Lindell for $1.3 billion for defamation, claiming he spread false conspiracy theories about them after the 2020 presidential election. COVID-19 pandemic – The United States surpasses 500,000 deaths from COVID-19. In response, President Biden orders flags to fly at half-mast for five days. February 23 Golf champion Tiger Woods is seriously injured in a car crash, and undergoes surgery at Harbor–UCLA Medical Center. February 24 – COVID-19 pandemic: Johnson & Johnson's vaccine candidate receives emergency use authorization from the FDA. The single-shot vaccine is 66% effective in combating the virus and can be stored in regular, unspecialized refrigerators. February 25 COVID-19 pandemic: The number of vaccines administered in the United States exceeds 50 million. The U.S. Food and Drug Administration approves Amondys 45 for the treatment of Duchenne muscular dystrophy. This is the first FDA-approved targeted treatment for people with the exon 45 skipping mutation. February 26 Washington's felony drug possession law is struck down as unconstitutional by the Washington Supreme Court, making Washington the 2nd state (after Oregon) to remove criminal penalties for possession of illicit drugs. Representative Paul Gosar and former Representative Steve King attend The America First Political Action Conference, whose organizer is Nick Fuentes. Gosar's attendance was the subject of controversy. February 27 The House of Representatives passes the American Rescue Plan Act, President Biden's $1.9 trillion COVID-19 relief package.
== Further reading == Snyder, Lloyd R.; Kirkland, Joseph J.; Dolan, John W. (2009). Introduction to Modern Liquid Chromatography. doi:10.1002/9780470508183. ISBN 978-0-470-16754-0. Dong, Michael W. (2006). Modern HPLC for Practicing Scientists. doi:10.1002/0471973106. ISBN 978-0-471-72789-7. Snyder, Lloyd R.; Kirkland, Joseph J.; Glajch, Joseph L. (1997). Practical HPLC Method Development. doi:10.1002/9781118592014. ISBN 978-0-471-00703-6. Ahuja, Satinder; Rasmussen, Henrik (2007). HPLC Method Development for Pharmaceuticals. Elsevier Science. ISBN 978-0-12-370540-2. Ahuja, Satinder; Dong, M. W. (2005). Handbook of pharmaceutical analysis by HPLC (1st ed.). Amsterdam Boston: Elsevier Academic Press. ISBN 978-0-12-088547-3. Kazakevich, Yuri; Lobrutto, Rosario, eds. (2007). HPLC for Pharmaceutical Scientists. doi:10.1002/0470087951. ISBN 978-0-471-68162-5. Neue, Uwe D. (1997). HPLC columns: theory, technology, and practice. New York, NY: Wiley VCH. ISBN 978-0-471-19037-0. McMaster, Marvin C. (2007). HPLC. doi:10.1002/0470079096. ISBN 978-0-471-75401-5.
=== Bond strain === This is the principal effect of induced fit binding, where the affinity of the enzyme to the transition state is greater than to the substrate itself. This induces structural rearrangements which strain substrate bonds into a position closer to the conformation of the transition state, so lowering the energy difference between the substrate and transition state and helping catalyze the reaction. However, the strain effect is, in fact, a ground state destabilization effect, rather than transition state stabilization effect. Furthermore, enzymes are very flexible and they cannot apply large strain effect. In addition to bond strain in the substrate, bond strain may also be induced within the enzyme itself to activate residues in the active site.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.